+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Janus kinase (JAK2) V617F somatic mutation in patients with deep vein thrombosis



Janus kinase (JAK2) V617F somatic mutation in patients with deep vein thrombosis








Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 021233066

Download citation: RISBibTeXText


Related references

The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. International Journal of Laboratory Hematology 30(5): 415-419, 2008

The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders. Haematologica 93(5): 787-788, 2008

Up-front Screening for the JAK2 V617F Mutation in Patients Presenting with Thrombosis other than Splanchnic Vein Thrombosis. Clinical Laboratory 61(11): 1813-1814, 2016

High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis. Hepatology 45(3): 831-2; Author Reply 832-3, 2007

JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis. JAMA 317(21): 2228-2229, 2017

The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México. Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 58(5): 458-461, 2007

Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis. International Journal of Laboratory Hematology 33(5): 471-476, 2012

Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 108(9): 3223-3224, 2006

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis. Turkish Journal of Gastroenterology 26(1): 42-48, 2015

JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders. Journal of Vascular Surgery 52(1): 205-207, 2010

Acute portal vein thrombosis in a 59-year-old male with JAK2 V617F mutation. Radiology Case Reports 13(6): 1249-1255, 2018

Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. American Journal of Hematology 82(5): 400-402, 2006

Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study. Thrombosis and Haemostasis 101(4): 787-789, 2009

Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?. Cerebrovascular Diseases 44(3-4): 97-104, 2017

The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 92(2): 285-286, 2007